Malignant Neoplasms

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

1 week ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement

2 months ago talkbio0Tagged Awareness, Dosage Forms, Health care facility, likeability, Malignant Neoplasms, Pfizer, Super Bowl 2025, Viewer Device, Weight-Loss Agents

Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs

Biotech IPOs Kick Off 2025: Ascentage Pharma Raises $126M, Aardvark Therapeutics Files for IPO

3 months ago talkbio0Tagged Ascentage, biotech, Drug Industry, IPOs, Malignant Neoplasms, Obesity, Order Tubulidentata (organism), Pharma

Biotech IPOs, Ascentage Pharma, Aardvark Therapeutics, Cancer Treatment, Obesity Treatment, Pharmaceutical Industry

GSK Initiates JPM Deal-making with $1 Billion Acquisition of IDRx for Rare Cancer Treatment

3 months ago talkbio0Tagged Acquisition, IDRx, JPM, Malignant Neoplasms, SmithKline Beecham

GSK, IDRx, JPM, rare cancer, acquisition, biotech, pharmaceuticals

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

5 months ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy